title: Electroacupuncture reduces the expression of proinflammatory cytokines in inflamed skin tissues through activation of cannabinoid CB2 receptors.
abstract: Endogenous cannabinoids and peripheral cannabinoid CB2 receptors (CB2Rs) are involved in the antinociceptive effect of electroacupuncture (EA) on inflammatory pain. However, it is not clear how CB2R activation contributes to the antinociceptive effect of EA. The major proinflammatory cytokines, such as tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-6, are involved in inflammatory pain. Here we determined the effects of CB2R activation and EA on the expression level of IL-1β, IL-6 and TNF-α in inflamed skin tissues. Inflammatory pain was induced by injection of complete Freund's adjuvant into the left hindpaw of rats. Thermal hyperalgesia was tested with a radiant heat stimulus, and mechanical allodynia was quantified using von Frey filaments. The mRNA and protein levels of IL-1β, IL-6 and TNF-α in inflamed skin tissues were measured using real-time polymerase chain reaction and Western blot, respectively. Local injection of the selective CB2R agonist AM1241 or EA applied to GB30 and GB34 significantly reduced thermal hyperalgesia and mechanical allodynia induced by tissue inflammation. The specific CB2R antagonist AM630 significantly attenuated the antinociceptive effect of EA. Furthermore, EA or AM1241 treatment significantly decreased the mRNA and protein levels of IL-1β, IL-6 and TNF-α in inflamed skin tissues. In addition, pretreatment with AM630 significantly reversed the inhibitory effect of EA on these cytokine levels in inflamed skin tissues. Our results suggest that EA reduces inflammatory pain and proinflammatory cytokines in inflamed skin tissues through activation of CB2Rs.
authors.affiliation: Department of Neurobiology and Key Laboratory of Neurological Diseases of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
authors.forename: T-F
authors.initials: TF
authors.lastname: Su
authors.forename: Y-Q
authors.initials: YQ
authors.lastname: Zhao
authors.forename: L-H
authors.initials: LH
authors.lastname: Zhang
authors.forename: M
authors.initials: M
authors.lastname: Peng
authors.forename: C-H
authors.initials: CH
authors.lastname: Wu
authors.forename: L
authors.initials: L
authors.lastname: Pei
authors.forename: B
authors.initials: B
authors.lastname: Tian
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: J
authors.initials: J
authors.lastname: Shi
authors.forename: H-L
authors.initials: HL
authors.lastname: Pan
authors.forename: M
authors.initials: M
authors.lastname: Li
mesh_terms: D000818:Animals; D002186:Cannabinoids / Q000494:pharmacology; D015671:Electroacupuncture; D006930:Hyperalgesia / Q000139:chemically induced / Q000378:metabolism*; D007211:Indoles / Q000494:pharmacology; D007249:Inflammation / Q000378:metabolism; D053583:Interleukin-1beta / Q000235:genetics / Q000378:metabolism*; D015850:Interleukin-6 / Q000235:genetics / Q000378:metabolism*; D008297:Male; D059408:Pain Management / Q000379:methods*; D010147:Pain Measurement; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D012867:Skin / Q000187:drug effects / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism*
chemical_list: C439263:AM 1241; D002186:Cannabinoids; C469526:Cnr2 protein, rat; D007211:Indoles; D053583:Interleukin-1beta; D015850:Interleukin-6; D012333:RNA, Messenger; D043885:Receptor, Cannabinoid, CB2; D014409:Tumor Necrosis Factor-alpha; C094023:iodopravadoline